Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model.
Researchers
Joris Holtrop, Mari N Gynnild, Salil V Deo, Carl-Emil Lim, Stelios Boulitsakis Logothetis, Kristi Läll, Minna Oksanen, Håvard Dalen, John Munkhaugen, Peter Ueda, Tomas Jernberg, José Tuñón, Ignacio Mahíllo Fernández, Ingvild Saltvedt, Hanne Ellekjær, Martin Teraa, Manon G van der Meer, Ynte M Ruigrok, Urmo Võsa, Małgorzata Chlabicz, Karol Kaminski, Ph Gabriel Steg, Ivana Burazor, Reedik Mägi, Taavi Tillmann, David A Wood, Kausik K Ray, Dirk de Bacquer, Janne Martikainen, John William McEvoy, Stephen Kaptoge, Frank L J Visseren, Emanuele Di Angelantonio, Deepak L Bhatt, Angela Wood, Steven H J Hageman, Jannick A N Dorresteijn
Abstract
The 2021 ESC guidelines on cardiovascular (CV) disease prevention recommend the SMART-REACH lifetime risk model to guide treatment decisions in patients with established atherosclerotic CV disease. The aim was to develop the SMART-REACH2 model for estimating lifetime risk of recurrent CV events and treatment benefits in patients with established atherosclerotic CV disease, with systematic recalibration to the four European and other global risk regions. SMART-REACH2 was derived in 8708 individuals aged 40-90 years with coronary, cerebrovascular, peripheral artery disease and/or abdominal aortic aneurysm from the UCC-SMART cohort. Sex-stratified, cause-specific Cox models for recurrent CV events and non-CV death were fitted using age as timescale and routinely available predictors. Recurrent CV events were defined as a composite of myocardial infarction, stroke, or CV death. Recalibration was based on representative cohorts per risk region. External validation was performed in 2 085 780 patients from 54 countries; model performance was assessed by calibration plots and Harrell's C-statistic. In the derivation cohort, 2057 recurrent CV events occurred over a median follow-up of 8.5 years (25th-75th: 4.3-13.0). In external validation, 307 706 events occurred. The pooled C-statistic was 0.68 (95% confidence interval 0.66-0.69) and ranged from 0.66 (0.64-0.69) for European low-risk region up to 0.72 (0.66-0.78) for Latin America, with adequate calibration across risk regions. Performance was consistent across sexes and CV disease subtypes. Using SMART-REACH2, estimated potential gains in CV disease-free life expectancy for a 50-year-old example patient receiving intensified preventive treatment (15 mmHg systolic blood pressure and 1.0 mmol/L low-density lipoprotein cholesterol reduction) ranged from 2 years in the low-risk region to 4.4 years in the very-high-risk region. The updated SMART-REACH2 model accounts for geographical and sex-specific variations and allows estimation of short-term and lifetime risk of recurrent CV events and treatment benefits, facilitating shared decision-making as recommended by guidelines.Source: PubMed (PMID: 42246978)View Original on PubMed